Crossmark

Clinical classification and molecular interpretation of germline pathogenic TP53 variations detected by multigene panel testing in patients with possible cancer predisposition

Crossref DOI link: https://doi.org/10.1007/s00438-025-02250-w

Published Online: 2025-04-24

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Onder, Gizem

Unal, Busra

Ozdemir, Ozkan

Amanvermez, Ufuk

Elmas, Merve Acıkel

Gokbayrak, Merve

Ugurtas, Cansu

Cine, Naci

Kalay, İrem

Ozbek, Ugur

Ng, Ozden Hatirnaz

Agaoglu, Nihat Bugra https://orcid.org/0000-0002-9336-0552
Funding

Funding for this research was provided by:

TÜBİTAK 2214-A International Research Fellowship Programme for PhD Students ((2022/2))

EJP RD (European Joint Programme on Rare Diseases) - The ERN (European Reference Networks (2023)

TUBITAK-2219-International Postdoctoral Research Scholarship (1059B192100905)
License Information

Text and Data Mining valid from 2025-04-24

Version of Record valid from 2025-04-24
More Information

Article History

Received: 27 December 2024

Accepted: 6 April 2025

First Online: 24 April 2025

Change Date: 24 September 2025

Change Type: Update

Change Details: The original online version of this article was revised to affiliation details of Nihat Bugra Agaoglu from 3,4,5,6,7,8,9 to 3,9 and affiliation details Ozden Hatirnaz Ng and Ozkan Ozdemir as 2,4.

Declarations

:

: This study has been approved by the ATADEK No:2022/15 30.09.2022.

: Informed consent was obtained from all subjects involved in the study.

Document is current

Any future updates will be listed below